Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease
Aim. To study the possible relationship between polymorphic variants of ABCB1 (rs2032582, rs1045642, rs1128503), CYP3A5 (rs776746), CYP3A4 (rs35599367) and CYP2J2 (rs890293) genes with residual equilibrium concentrations (Cmin,ss) of rivaroxaban in patients with non-valvular atrial fibrillation (AF)...
Main Authors: | N. A. Shatalova, D. A. Sychev, K. B. Mirzaev, A. I. Kochetkov, E. Yu. Ebzeeva, V. B. Dashabylova, P. O. Bochkov, S. N. Tuchkova, S. V. Glagolev |
---|---|
Format: | Article |
Language: | English |
Published: |
Столичная издательская компания
2023-11-01
|
Series: | Рациональная фармакотерапия в кардиологии |
Subjects: | |
Online Access: | https://www.rpcardio.online/jour/article/view/2970 |
Similar Items
-
Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions
by: Natalia A. Shnayder, et al.
Published: (2021-04-01) -
Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis
by: L. V. Fedina, et al.
Published: (2023-01-01) -
A review of pharmacogenetics of anticoagulant therapy: Heparins, rivaroxaban, apixaban, and dabigatran
by: Ali Mohammed Abd Alridha, et al.
Published: (2022-01-01) -
The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016-11-01) -
Population Pharmacokinetics and Dose Optimization Based on Renal Function of Rivaroxaban in Thai Patients with Non-Valvular Atrial Fibrillation
by: Noppaket Singkham, et al.
Published: (2022-08-01)